Clinical trial
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In…
NCT00066196 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00066196 |
|---|---|
| Title | Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma |
| Official title | A Phase II, Randomized, Open-Label Study Evaluating The Antitumor Activity Of MEDI-522, A Humanized Monoclonal Antibody Directed Against The Human Alpha V Beta 3 Integrin, ± Dacarbazine In Patients With Metastatic Melanoma |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Malignant Metastatic Melanoma |
| Intervention type | Biological |
| Interventions | MEDI--522, Integrin + Dacarbazine |
| Enrollment | 110 |
| Start date | Aug 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Aug 7, 2003 |
| Last update posted | Jan 15, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: